Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Drug Discovery
Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Cobroxin
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Overview

Drug Discovery ResearchReceptoPharm (website) is the Nutra Pharma holding that acts as the drug discovery arm for the Company. ReceptoPharm is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases in humans. The emphasis of ReceptoPharm's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra.

Leading Drug Candidates

RPI-MN
RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and AIDS. It is being developed first for the treatment of HIV.
 
 
RPI-78M
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
 

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to ReceptoPharm, the drugs are created through a process of chemical modification and possess several desirable properties as drugs, including:

  • They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
  • They display no serious adverse side effects following years of investigations in humans and animals.
  • They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
  • They are easy to administer.
  • RPI-78M can be administered orally-a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
January 07, 2014
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs


December 02, 2013
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin


November 11, 2013
Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin®


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics